H. S. Friedman

3.5k total citations
50 papers, 2.4k citations indexed

About

H. S. Friedman is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, H. S. Friedman has authored 50 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in H. S. Friedman's work include Glioma Diagnosis and Treatment (24 papers), Neuroblastoma Research and Treatments (10 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). H. S. Friedman is often cited by papers focused on Glioma Diagnosis and Treatment (24 papers), Neuroblastoma Research and Treatments (10 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). H. S. Friedman collaborates with scholars based in United States, Sweden and Australia. H. S. Friedman's co-authors include Sandra H. Bigner, Darell D. Bigner, Michael R. Zalutsky, D D Bigner, Gary E. Archer, Gregory N. Fuller, Roger E. McLendon, Peter A. Humphrey, Albert J. Wong and Madan M. Kwatra and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

H. S. Friedman

47 papers receiving 2.4k citations

Peers

H. S. Friedman

GENET

ONCOL

PRM

RNMI

Teri Kreisl United States

Matthias Holdhoff United States

Lyndon Kim United States

Baldassarre Stea United States

Carmen Balañá Spain

Christopher E. Pelloski United States

L. Magnus Bäcklund Sweden

Benoît Lhermitte France

Jeannette M. Dowell United States

Magalie Hilton Switzerland

Teri Kreisl United States

H. S. Friedman

1.7k ×1.8

GENET

722 ×0.8

443 ×0.7

ONCOL

713 ×1.1

PRM

355 ×0.6

RNMI

Citations per year, relative to H. S. Friedman H. S. Friedman (= 1×) peers Teri Kreisl

Countries citing papers authored by H. S. Friedman

Since Specialization

Citations

This map shows the geographic impact of H. S. Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. S. Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. S. Friedman more than expected).

Fields of papers citing papers by H. S. Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. S. Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. S. Friedman. The network helps show where H. S. Friedman may publish in the future.

Co-authorship network of co-authors of H. S. Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of H. S. Friedman. A scholar is included among the top collaborators of H. S. Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. S. Friedman. H. S. Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schold, S. Clifford & H. S. Friedman. (2015). Human Brain Tumor Xenografts. Progress in tumor research. 28. 18–31.

Sumrall, Ashley, David A. Reardon, Annick Desjardins, et al.. (2011). Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial.. Journal of Clinical Oncology. 29(15_suppl). 9090–9090.

Bacolod, Manny D., Sihan Lin, Scott A. Johnson, et al.. (2008). The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide. Current Cancer Drug Targets. 8(3). 172–179. 33 indexed citations

Houghton, Peter J., John M. Maris, H. S. Friedman, et al.. (2006). 313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992). European Journal of Cancer Supplements. 4(12). 98–98. 2 indexed citations

Friedman, H. S., Demetrius M. Kokkinakis, James M. Pluda, et al.. (1998). Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.. Journal of Clinical Oncology. 16(11). 3570–3575. 160 indexed citations

Graham, Michael L., James E. Herndon, Joseph R. Casey, et al.. (1997). High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.. Journal of Clinical Oncology. 15(5). 1814–1823. 132 indexed citations

Mahoney, Donald H., Douglas Strother, BM Camitta, et al.. (1996). High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study.. Journal of Clinical Oncology. 14(2). 382–388. 81 indexed citations

Vaidyanathan, Ganesan, et al.. (1996). Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. British Journal of Cancer. 73(10). 1171–1177. 10 indexed citations

McCowage, Geoffrey, H. Dirk Sostman, David M. Brizel, et al.. (1996). Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.. PubMed. 37(9). 1438–44. 124 indexed citations

10.

Osumi, Alan K., Roger E. McLendon, R D Tien, et al.. (1995). Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma.. PubMed. 13(5). 281–5. 14 indexed citations

11.

Rasheed, Binish, et al.. (1995). Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.. PubMed. 10(11). 2243–6. 164 indexed citations

12.

Tien, R D, et al.. (1994). Gadolinium enhancement of the leptomeninges caused by hydrocephalus: a potential mimic of leptomeningeal metastasis.. American Journal of Neuroradiology. 15(4). 639–41. 14 indexed citations

13.

Dolan, M. Eileen, et al.. (1994). Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.. PubMed. 54(19). 5123–30. 50 indexed citations

14.

Wikstrand, Carol J., Roger E. McLendon, Gregory N. Fuller, et al.. (1993). Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.. PubMed. 53(1). 120–6. 23 indexed citations

15.

Friedman, H. S., Jeffrey P. Krischer, P. C. Burger, et al.. (1992). Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.. Journal of Clinical Oncology. 10(2). 249–256. 143 indexed citations

16.

Friedman, H. S. & W. Jerry Oakes. (1992). New therapeutic options in the management of childhood brain tumors.. PubMed. 6(5). 27–36; discussion 36, 39. 5 indexed citations

17.

Saylors, Robert L., David Sidransky, H. S. Friedman, et al.. (1991). Infrequent p53 gene mutations in medulloblastomas.. PubMed. 51(17). 4721–3. 163 indexed citations

18.

Friedman, H. S., S. Clifford Schold, W T Djang, et al.. (1989). Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. Neurology. 39(1). 62–62. 8 indexed citations

19.

Friedman, H. S., S. Clifford Schold, M. S. Mahaley, et al.. (1989). Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma.. Journal of Clinical Oncology. 7(7). 904–911. 48 indexed citations

20.

Schold, S. Clifford, M. S. Mahaley, Nicholas A. Vick, et al.. (1987). Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.. Journal of Clinical Oncology. 5(3). 464–471. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact